Showing papers by "Todd E. DeFor published in 2001"
TL;DR: It is suggested that despite increased HLA disparity, probabilities of engraftment, GVHD, and survival after UCB transplantation are comparable to those observed after HLA-matched BM transplantation, and UCB should be considered an acceptable alternative to HLA -mismatched BM for pediatric patients.
388 citations
TL;DR: The data suggest that despite a high response rate and encouraging survival rates, thalidomide offers no clinical benefit when incorporated into initial therapy for CGVHD, and the value of thalidmide as salvage therapy requires further study.
118 citations
TL;DR: The incidence of EBV-PTLD after unrelated-donor UCBT appears similar to that observed after transplantation using unrelated bone marrow (BM) and compares favorably with unrelated-Donor T-cell-depleted BM transplantation.
90 citations
TL;DR: Transplantation of bone marrow from a matched sibling donor or an HLA-A,B/DRB1-matched unrelated donor produces equivalent outcomes in patients with chronic myelogenous leukemia, particularly if the transplant takes place within 1 year after diagnosis.
60 citations
TL;DR: The overall survival rate was 35% at 2 years following the onset of enteritis, and the methods used in diagnosis included histopathology and virology, and most treatment regimens included ganciclovir.
51 citations
TL;DR: It is found that there is no significant association between engraftment, marrow cell dose and BU exposure when combined with CY and TBI in children with IMSD.
Abstract: Allogeneic hematopoietic cell transplantation (HCT) is the only treatment for selected inherited metabolic storage diseases (IMSD); a significant shortcoming is failure to achieve donor-derived engraftment. This study was undertaken to determine whether busulfan pharmacokinetics (BU PK) are altered in children with IMSD and whether BU concentrations are important in achieving engraftment. BU samples were obtained from 39 IMSD children, including 20 children with Hurler syndrome, undergoing HCT. Patients received oral BU (40 mg/m(2)/dose x 8 doses), cyclophosphamide (60 mg/kg/day x 2 doses) and TBI (750 cGy in one fraction) as a preparative regimen. Median (range) oral clearance corrected for bioavailability (Cl/F in ml/min/kg), area under the curve (AUC in ng min/ml) and BU plasma concentration (Cp in ng/ml) with the fourth dose were 5.2 (2.1-11.4), 318 294 (112 893-640 995) and 950 (314-1780), respectively. Children < 3 years of age had lower AUC and Cp but higher Cl/F (P < or = 0.03). BU Cp (P = 0.06) or marrow cell dose (P = 0.32) was not different in Hurler syndrome compared to other IMSD. A median BU Cp of 959 and 831 ng/ml was achieved in children with full and failed early engraftment, respectively. There was no difference in early and late engraftment between children with Hurler and other IMSD. In conclusion, we found no significant association between engraftment, marrow cell dose and BU exposure when combined with CY and TBI in children with IMSD.
17 citations